Illumi Medical develops the ET-BLIT intravascular light irradiation system, which uses a thin catheter inserted via a transvascular approach to emit light through vessel walls to reach deep-seated tissues. The technology is intended to enable applications of light-based therapies such as photodynamic therapy (PDT) and near-infrared photoimmunotherapy (NIR-PIT) for cancers and neurological diseases previously inaccessible to external light. The company says the procedure can be performed in existing cardiac catheterization rooms. Illumi Medical was established in February 2023. With the completion of its ¥550 million Series A, the company plans to advance product development, transition manufacturing to mass production, secure supply and quality for clinical trials, and execute global regulatory and insurance strategies. It also intends to expand treatment and diagnostic pipelines through alliances with pharmaceutical companies and pursue international joint clinical trials and overseas approvals.

Total raised

$8M

Funding rounds

3

Latest round

Series A

Latest activity

May 2026